Therapeutics Stocks Q1 Earnings: Moderna Leads, United Therapeutics Lags

Earnings
โดย StockStory·Read original
Summary · why it matters

Among 11 therapeutics stocks tracked, first-quarter revenues beat analysts' consensus estimates by 14.5% on average. Moderna reported revenues of $389 million, up 260% year on year and exceeding expectations by 55.8%, making it the best performer in the group. United Therapeutics posted the weakest results with revenues of $781.5 million, down 1.6% year on year and missing estimates by 1.9%. Gilead Sciences reported revenues of $6.96 billion, up 4.4% year on year and beating expectations by 1.5%, but its full-year EPS guidance missed significantly. Novavax recorded the biggest analyst estimate beat with revenues of $139.5 million, down 79.1% year on year but surpassing expectations by 84.5%, while Myriad Genetics reported revenues of $200.4 million, up 2.3% year on year and missing estimates by 1%.

Impact on stocks 5

Biotech & Genomic Medicine± Mixed · 5 stocks
Moderna Inc
MRNA
▲ PositiveCapitalrelevance

Revenues up 260% YoY, beating expectations by 55.8%, best performer.

Novavax Inc
NVAX
▲ PositiveCapitalrelevance

Revenues beat expectations by 84.5%, biggest analyst estimate beat.

Gilead Sciences Inc
GILD
± MixedCapitalrelevance

Revenues beat estimates but full-year EPS guidance missed significantly.

© 2026 MarketDXNews